SpyGlass Pharma, Inc.
SGP- Exchange
- Nasdaq
- Industry
- Surgical & Medical Instruments & Apparatus
- SEC CIK
- 0001778922
In the last 90 days, SpyGlass Pharma, Inc. insiders filed 1 open-market purchase and 0 sales; 69 institutions reported holding it in 13F filings for Q3 2026, worth $687.8M in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 19, 2026
- $1.03B
- Insider buysLast 90 days, $32.4K in total
- 1
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ3 2026, +18 vs. previous quarter
- 69
- 13F valueReported value at the end of Q3 2026
- $687.8M
- Superinvestors holdingAt the end of Q3 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- –
- No comparable prior period
- Net income, FY2025
- -$39.9M
- No comparable prior period
- Free cash flow, FY2025
- -$33.5M
- No comparable prior period
- Revenue, Q3 FY2026
- –
- No comparable prior period
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 1.16M
- Shares sold short
- Change
- −63.8K
- −5.2% vs. previous
- Days to cover
- 12.05
- At average daily volume
Superinvestors holding SGP, Q3 2026
Go to the superinvestors tabNo superinvestor reported holding SGP at the end of Q3 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by SpyGlass Pharma, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 18, 2026 (view filing)4:56 PM ET | Nov 16 | 2 days | RA Capital Healthcare Fund LP and 4 othersDirector, 10% Owner | PPurchase | +1.00K | $32.43 | +$32.4K | 0.0%5.97M after | |
| Feb 11, 2026 (view filing)5:15 PM ET | Feb 9 | 2 days | RA Capital Healthcare Fund LP and 4 othersDirector, 10% Owner | PPurchase | +3.69M | $16.00 | +$59.0M | New position2.05M after | 2 lots |
| Feb 11, 2026 (view filing)4:30 PM ET | Feb 9 | 2 days | New Enterprise Associates 17, L.P. and 2 others10% Owner | PPurchase | +937.5K | $16.00 | +$15.0M | +18.4%6.04M after | Duplicate filing |
| Feb 11, 2026 (view filing) | Feb 9 | 2 days | Khan Bilal ArshadDirector | PPurchase | +20.0K | $16.00 | +$320.0K | +367.0%25.4K after | |
| Feb 11, 2026 (view filing) | Feb 9 | 2 days | Khan Bilal ArshadDirector | PPurchase | +115.0K | $16.00 | +$1.84M | +84.3%251.4K after | |
| Feb 11, 2026 (view filing) | Feb 9 | 2 days | Pardo Geoffrey BDirector | PPurchase | +312.5K | $16.00 | +$5.00M | +16.7%2.19M after | |
| Feb 11, 2026 (view filing) | Feb 9 | 2 days | Behbahani AliDirector, 10% Owner | PPurchase | +937.5K | $16.00 | +$15.0M | +18.4%6.04M after | Duplicate filing |
| Feb 11, 2026 (view filing) | Feb 9 | 2 days | Florence Anthony A. Jr.10% Owner | PPurchase | +937.5K | $16.00 | +$15.0M | +18.4%6.04M after | Duplicate filing |
| Feb 11, 2026 (view filing) | Feb 9 | 2 days | Baskett Forest10% Owner | PPurchase | +937.5K | $16.00 | +$15.0M | +18.4%6.04M after | Duplicate filing |
| Feb 11, 2026 (view filing) | Feb 9 | 2 days | Yang Rick10% Owner | PPurchase | +937.5K | $16.00 | +$15.0M | +18.4%6.04M after | Duplicate filing |
Top 10 13F holders, Q3 2026
See all 69 holdersThe largest institutional positions in SpyGlass Pharma, Inc. at the end of Q3 2026; share changes are against Q2 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Ra Capital Management, L.P. | 8,021,117 | $208.5M | 2.09% | 00.0% | Unchanged |
| NEA Management Company, LLC | 7,392,301 | $192.2M | 14.09% | 00.0% | Unchanged |
| Sands Capital Ventures, LLC | 2,500,012 | $65.0M | 9.36% | 00.0% | Unchanged |
| Samsara BioCapital, LLC | 2,109,953 | $54.9M | 5.22% | 00.0% | Unchanged |
| JPMorgan Chase & Co | 1,003,268 | $25.5M | 0.00% | +373,529+59.3% | Added |
| Price T Rowe Associates Inc | 925,767 | $24.1M | 0.00% | +251,624+37.3% | Added |
| Vanguard Capital Management LLC | 660,821 | $17.2M | 0.00% | +226,398+52.1% | Added |
| Vestal Point Capital, LP | 640,000 | $16.6M | 0.43% | −30,000−4.5% | Reduced |
| BlackRock, Inc. | 630,409 | $16.4M | 0.00% | −81,303−11.4% | Reduced |
| Standard Life Aberdeen plc | 506,502 | $13.2M | 0.02% | +13,426+2.7% | Added |
Holders of 5% or more of SGP
See all 6 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of SpyGlass Pharma, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Ra Capital Management, L.P. | 13D | 24.10%8.02M shares | New | Feb 17, 20261 filing | Feb 17, 2026 | SEC |
| New Enterprise Associates 17, L.P. | 13D | 22.20%7.39M shares | New | Feb 13, 20261 filing | Feb 13, 2026 | SEC |
| Vensana Capital I GP, LLC | 13D/A | 8.90%2.99M shares | −1.00 ppfrom 9.90% | Feb 10, 20262 filings | Nov 18, 2026 | SEC |
| Sands Capital Life Sciences Pulse Fund III (DE), L.P. | 13G | 7.80%2.50M shares | New | Feb 13, 20261 filing | Feb 13, 2026 | SEC |
| Gilde Healthcare Holding B.V. | 13D | 6.57%2.19M shares | New | Feb 13, 20261 filing | Feb 13, 2026 | SEC |